Rucha Patil: Advancing Haemostasis Through Science, Collaboration and Innovation at NHU 2026
Rucha Patil, Scientist at Department of Haemostasis and Thrombosis, ICMR- National Institute of Immunohaematology, shared a post on LinkedIn:
“NHU 2026 | Advancing Haemostasis Through Science, Collaboration and Innovation
The 15th National Haemostasis Update (NHU) 2026, held on 1–2 August 2026 in Bengaluru, Organised by the Indian Association for Haemophilia and Allied Disorders (IAHAD) brought together clinicians, nurses, physiotherapists, researchers, and allied healthcare professionals from across India with a shared vision of advancing care for people with haemophilia and other bleeding disorders.
The conference concluded on an exceptionally proud note, with three outstanding laboratory research studies from our team being awarded the Best Poster Awards:
- A Novel Emicizumab-Compatible Lateral Flow Immunoassay for Rapid Detection of Factor VIII Inhibitors
(Rucha Patil, Sharda Shanbhag, Sweta Kaskar, Moni Singh) - Immunogenetic Basis of Factor VIII Inhibitor Development in Severe Haemophilia A Patients: Integrated Analysis of Immune Cell Profiling, Cytokine Signatures, Immune Gene Polymorphisms & Whole Exome Sequencing (sharda shanbhag, Karishma Vyas, Bipin Kulkarni, Rucha Patil)
- Prenatal Insight into a Rare Dual-Lineage Compound Heterozygous Female Foetus Affected by Haemophilia A(Karishma Vyas, Nikesh Kawankar, Babita Phartyal, Rucha Patil, Bipin Kulkarni, Sharda Shanbhag)
Adding another moment of pride, the Best Oral Presentation Award was for:
Real-World Clinical Experience with Very Low-Dose Emicizumab Prophylaxis in Hemophilia A: ‘A Single-Centre Study from a Tertiary Care Institute’ a KEM-ICMR study (Kalpita Pai, Rucha Patil, Kirti Patil, Jai Juverkar, Sayali Rasal)
These recognitions reflect the dedication, teamwork, and commitment of our group towards advancing innovative diagnostics, precision medicine, and improved therapeutic strategies in haemophilia care.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke